CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...
Phase 1, Phase 2
Washington, District of Columbia, United States and 20 other locations
fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate ...
Phase 2
Baltimore, Maryland, United States and 10 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
Washington, District of Columbia, United States and 187 other locations
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...
Phase 1
Fairfax, Virginia, United States and 20 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Fairfax, Virginia, United States and 202 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Silver Spring, Maryland, United States and 82 other locations
choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...
Phase 3
Wheaton, Maryland, United States and 168 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
Fairfax, Virginia, United States and 73 other locations
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors....
Phase 1
Fairfax, Virginia, United States and 1 other location
in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-re ...
Phase 1
Washington, District of Columbia, United States and 17 other locations
Clinical trials
Research sites
Resources
Legal